Sands Capital released its Q2 2025 investor letter, noting strong U.S. large-cap growth equities performance driven by corporate earnings and AI optimism. The portfolio returned 27.7%, outperforming the Russell 1000 Growth Index. Top holdings include Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focusing on rare genetic diseases, with shares closing at $29.00.

In the investor letter, Sands Capital highlighted Ultragenyx Pharmaceutical Inc. (RARE) as a leading developer of rare disease treatments. The company’s stock was unchanged in Q2 as investors awaited Phase 3 trial results. Ultragenyx’s expanding commercial franchise and pipeline present a long-term opportunity, despite recent setbacks.

Ultragenyx Pharmaceutical Inc. (RARE) saw 13% revenue growth in Q2 2025, with 60 hedge funds holding its stock. While acknowledging Ultragenyx’s potential, Sands Capital believes certain AI stocks offer better returns and less risk. Investors seeking undervalued AI opportunities can explore our report on the best short-term AI stock.

Read more at Yahoo Finance: Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity?